Altered p16(INK4) and retinoblastoma protein status in non-small cell lung cancer: Potential synergistic effect with altered p53 protein on proliferative activity

Cancer Research

Volumn 56, Issue 24, 1996, Pages 5557-5562

  Kinoshita, Ichiro ^a   Dosaka Akita, Hirotoshi ^a   Mishina, Takayuki ^a   Akie, Kenji ^a   Nishi, Motoi ^b   Hiroumi, Hiromitsu ^a   Hommura, Fumihiro ^a   Kawakami, Yoshikazu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67; ONCOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; CARRIER PROTEIN; KI 67 ANTIGEN; PROTEIN P16INK4A; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE DOSAGE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SMOKING; TUMOR SUPPRESSOR GENE; CELL DIVISION; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029658335     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Weinberg, R. A The retinoblastoma protein and cell cycle control Cell. 81: 323-330, 1995.
2. Kamb, A , Gruis, N. A , Weaver-Feldhaus, J., Liu, Q , Harshman, K., Tavtigian, S V , Stockert, E , Day, R S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
3. Nobori, T., Miura, K., Wu, D J., Lois, A., Takabayashi, K. and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
4. Serrano, M., Hannon, G. J , and Beach, D A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond ), 366: 704-707, 1993.
5. INK4B is a potential effector of TGF-β-induced cell cycle arrest Nature (Lond ), 371: 257-261, 1994.
6. Lukas, J , Parry, D , Aagaard, L., Mann, D. J., Bartkova, J , Strauss, M., Peters, G., and Bartek, J. Retinoblastoma protein-dependent cell-cycle inhibition by the tumour suppressor p16 Nature (Lond.), 375: 503-506, 1995.
7. INK4 in human cancer. Proc Natl. Acad. Sci USA, 91: 11045-11049, 1994
8. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB Oncogene, 9: 3375-3378, 1994.
9. INK4. Cancer Res., 54: 5816-5820, 1994
10. INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
11. Kelley, M. J., Nakagawa, K , Steinberg, S. M , Mulshine, I. L., Kamb, A., and Johnson, B E. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J. Natl. Cancer Inst , 87: 756-761, 1995.
12. INK4 protein induction by 5-aza 2′deoxycytidine Oncogene, 11: 1211-1216, 1995.
13. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55: 6006-6011, 1995.
14. Xu, H-J , Hu, S-X., Cagle, P T., Moore, G. E., and Benedict, W. F. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas Cancer Res., 51: 2735-2739, 1991.
15. Reissmann, P T , Koga, H., Takahashi, R , Figlin, R A , Holmes, E C., Piantadosi, S., Cordon-Cardo, C , Slamon, D. J , and the Lung Cancer Study Group. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene, 8: 1913-1919, 1993
16. Xu, H-J , Quinlan, D. C , Davidson, A G., Hu, S-X , Summers, C L., Li, J., and Benedict, W F Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma J Natl. Cancer Inst., 86 695-699, 1994.
17. Shimizu, E , Coxon, A , Otterson, G A , Steinberg, S M , Kratzke, R A , Kim, Y. W , Fedorko, J., Oie, H., Johnson, B E , Mulshine, J L , Minna, J D , Gazdar, A. F , and Kaye, F. J RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene, 9: 2441-2448, 1994.
18. Higashiyama, M., Doi, O , Kodama, K., Yokouchi, H , and Tateishi, R Retinoblastoma protein expression in lung cancer, an immunohistochemical analysis. Oncology, 51: 544-551, 1994.
19. Liu, Q , Neuhausen, S , McClure, M., Frye, C., Weaver-Feldhaus, J , Gruis, N. A., Eddington, K., Allalunis-Turner, M. J., Skolnick, M. H., Fujimura, F K., and Kamb, A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10: 1061-1067, 1995.
20. Washimi, O , Nagatake, M., Osada, H , Ueda, R., Koshikawa, T., Seki, T., Takahashi, T., and Takahashi, T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res., 55: 514-517, 1995.
21. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer Cancer Res., 55: 1448-1451, 1995
22. Nakagawa, K , Conrad, N K., Williams, J P , Johnson, B. E , and Kelley, M J. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage Oncogene, 11, 1843-1851, 1995.
23. Hayashi, N., Sugimoto, Y , Tsuchiya, E , Ogawa, M., and Nakamura, Y. Somatic mutations of the MTS (multiple tumor suppressor) I/CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas Biochem. Biophys. Res. Commun., 202: 1426-1430, 1994
24. Cairns, P., Mao, L., Merlo, A , Lee, D. J , Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J E., and Sidransky, D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (Washington DC), 265: 415-417, 1994.
25. Greenblatt, M. S., Bennett, W P., Hollstein, M., and Harris, C. C Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res , 54: 4855-4878, 1994
26. Cordon-Cardo, C. Mutation of cell cycle regulators, biological and clinical implications for human neoplasia Am J Pathol., 147: 545-560, 1995.
27. Dosaka-Akita, H., Shindoh, M , Fujino, M , Kinoshita, I., Akie, K., Katoh, M , and Kawakami, Y. Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am. J. Clin. Pathol , 102: 660-664, 1994.
28. Reed, J A., Loganzo, F., Jr, Shea, C. R., Walker, G. J., Flores, J. F., Glendening, J. M., Bogdany, J. K., Shiel, M. J., Haluska, F. G., Fountain, J. W , and Albino, A. P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55: 2713-2718, 1995
29. Pence, J. C , Kerns, B J , Dodge, R. K., and Iglehart, J. D. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch. Surg., 128: 1382-1390, 1993.
30. Mehta, C. R , and Patel, N. R. A network algorithm for performing Fisher's exact test in r X c contingency tables. J. Am Stat. Assoc., 78: 427-434, 1983.
31. Cox, D , and Snell, E. Analysis of Binary Data. Ed 2. London. Chapman and Hall, 1989
32. Gerdes, J., Lemke, H., Baisch, H , Wacker, H-H , Schwab, U., and Stein, H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol., 133: 1710-1715, 1984.
33. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078-6082, 1994.
34. Sakaguchi, M., Yoshitaka, F., Hirabayashi, H., Yoon, H-E., Komoto, Y., Oue, T , Kusafuka, T., Okada, A., and Mitsuda, H. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int. J. Cancer , 65: 442-445, 1996.
35. Belinsky, S. A., Nikula, K J , Baylin, S B., and Issa, J-P. J. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer, Proc. Natl. Acad. Sci. USA, 93: 4045-4050, 1996
36. Ebina, M., Steinberg, S. M., Mulshine, J. L., and Linnoila, R. I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res , 54: 2496-2503, 1994.
37. Harpole, D. H., Jr., Herndon, J. E I , Wolfe, W. G., Iglehart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression Cancer Res., 55: 51-56, 1995.
38. Huang, H-J S., Yee, J-K., Shew, J-Y., Chen, P-L., Bookstein, R., Friedmann, T., Lee, E Y-H. P, and Lee, W-H Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells Science (Washington DC), 242: 1563-1566, 1988.
39. Crook, T., Marston, N. J., Sara, E A , and Vousden, K H. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell, 79: 817-827, 1994.